Skip to main content
Poxel logo

Poxel — Investor Relations & Filings

Ticker · POXEL ISIN · FR0012432516 LEI · 9695003OIX0T7NX72N26 PA Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2026-05-20 Earnings Release
Country FR France
Listing PA POXEL

About Poxel

https://www.poxelpharma.com/en_us

Poxel is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic diseases, particularly non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. The company's pipeline features two mid-stage candidates: PXL065, a deuterium-stabilized R-pioglitazone for NASH that has completed a Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator for rare diseases. Additionally, Poxel's product TWYMEEG® (Imeglimin) is approved and marketed in Japan by Sumitomo Pharma for the treatment of type 2 diabetes, providing the company with royalties and sales-based payments.

Recent filings

Filing Released Lang Actions
Quarterly financial reporting / First quarter financial report
Earnings Release Classification · 94% confidence The document is a corporate press release titled “Poxel Reports First Quarter 2026 Revenue and Provides a Business Update,” presenting key quarterly sales and revenue figures, business milestones, and guidance. It does not include full financial statements or detailed analysis, but provides highlighted results for the quarter—consistent with an Earnings Release. Therefore, it should be classified as an initial announcement of quarterly financial results. Q1 2026
2026-05-20 English
Information financière trimestrielle / Information financière du premier trimestre
Earnings Release Classification · 88% confidence The document is a press release (‘Communiqué de presse’) announcing Poxel’s consolidated revenue for the first quarter ended March 31, 2026, with key sales figures and growth statistics. It provides headline financial results (Q1 2026 net sales), brief commentary on royalty agreements and outlook, but does not include full financial statements or substantive analysis as in a quarterly report. This matches the definition of an Earnings Release (ER). Q1 2026
2026-05-20 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 85% confidence The document is a mandatory regulatory disclosure under French law (AMF Article 223-16 and Code de Commerce) providing the total number of shares and voting rights as of a given date. It does not announce a specific financing or share issue, nor is it a shareholder vote result, annual or interim report, or proxy material. It is a general regulatory filing of share capital/voting rights information, fitting the fallback category. Therefore, it should be classified as a general Regulatory Filing (RNS).
2026-05-13 French
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 100% confidence The document is a press release from Poxel SA announcing the postponement of the publication of its annual financial statements and annual report for the fiscal year ending December 31, 2025. It details reasons for the delay, including significant financial operations and capital increases, and provides a revised schedule for the publication of the annual report and the annual general meeting. The document does not contain the actual annual report or financial statements but rather announces the delay and updated timeline. It is a communication about the timing of a report, not the report itself. Therefore, according to the 'Menu vs Meal' rule, this document should be classified as a Report Publication Announcement (RPA).
2026-04-30 French
Inside Information / Other news releases
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the postponement of the publication of the 2025 annual financial statements and the annual financial report. It provides details about the reasons for the delay, including significant transactions and their accounting treatment, and updates the tentative financial calendar for the approval and publication of the annual financial statements and report. The document does not contain the actual financial statements or the full annual report itself but rather informs the market about the delay and the new expected dates. The length is about 5071 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the 'Menu vs Meal' rule, this document should be classified as a Report Publication Announcement (RPA) rather than the Annual Report (10-K).
2026-04-30 English
Inside Information / Operations of the issuer (acquisitions, sales...)
Capital/Financing Update Classification · 82% confidence The document is a press release announcing Poxel’s definitive agreement to sell its drug candidate PXL770 to Scynexis, detailing upfront payments and milestone payments. This is a financing transaction rather than an earnings update or regulatory report. It describes a capital‐raising/asset‐sale arrangement (upfront and milestone payments), so it best fits under “Capital/Financing Update” (CAP).
2026-03-31 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.